Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.62 EUR-1.22 %7/9 13:11
5,677 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-1.22 %
+1.38 %
+13.92 %
-37.69 %
-57.03 %
-57.26 %
-48.08 %
-88.18 %
-64.63 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
34.82M EUR
Turnover
91.01K EUR
P/E (adj.) (26e)
-12.8
EV/EBIT (adj.) (26e)
-9.18
P/B (26e)
1.63
EV/S (26e)
1.7
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
2026-08-17
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 2026-08-17

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Millions in cash are coming to Veikkausliiga and the clubs from new gambling companies. Ubetec’s 0.5-1M project (and the ongoing annual revenue after that) is peanuts in the big picture for a new entrant. The essential thing is to get the operation working right away. Not many companies...
6 hours ago
by Sheikki
24
The spin-off was done precisely because Optomed’s core business remains fundus cameras. Ubetec focuses on the gaming market with its own personnel and strategy. Ubetec’s packaging is downright ingenious (cooperating with Nordic Legal Hero) where they consult and implement the technical...
yesterday
by Dr.Feelgood
17
If the market opens at the turn of the year, hardly any operator will be able to start operations without its compliance infrastructure (such as the Ubetec Vault data collection vault and responsible gaming reporting APIs) being not only coded, but also tested and audited in accordance...
20 hours ago
by Mr. Stock
16
It looks like there are at least 57 applicants. Spinning off the gambling supervision into its own company is completely normal, logical, and sensible. The reasons include industry differences, reporting, and different business growth prospects. In this particular business, the near...
22 hours ago
by Sheikki
9
Here are Juha’s comments on how Optomed’s subsidiary Ubetec Oy won Veikkaus Oy’s competitive bidding process. Optomed announced on Friday that its subsidiary Ubetec Oy has won the competitive bidding process regarding Veikkaus Oy’s gaming compliance services. The total value of the...
1 hour ago
by Sijoittaja-alokas
8
[quote="Mr_Stock, post:6736, topic:2389"]\ninvestment in the Ubetec business, which produced its first contract 9 months later.\n[/quote]\n\nUbetec, which was founded in 9/2024, of course already had prior business before this Veikkaus contract. Coincidentally, in that same month...
21 hours ago
by Sheikki
7
Q2 2026 Inderes interview and starting from 7:30 => “we have several competitive bidding processes ongoing that we are participating in, and with a high probability, we will win some of them. That means during the H2 half, there will be major delivery projects and through that also...
17 hours ago
by Mr. Stock
6
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

4/5
2027

Interim report Q1'27

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande
Analyst Comment2026-09-07 06:55 by
Juha Kinnunen

Optomeds dotterbolag Ubetec vann Veikkauchs anbudsförfarande

Veikkaus avtalstilldelning på 0,9 MEUR stärker dotterbolaget Ubetecs position på den finländska spelmarknaden som håller på att öppnas upp.

Optomed
Regulatory press release2026-09-04 14:00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed
Press release2026-08-18 13:10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer
Research2026-08-17 07:00 by
Juha Kinnunen

Optomed Q2'26: Apparatförsäljningen drar inte, men de återkommande intäkterna växer

Optomeds omsättning och vinst i Q2 var betydligt lägre än våra förväntningar, då försäljningen av utrustning fortsatte att vara svag. Positivt i rapporten var den fortsatta tillväxten i försäljningen av Aurora AEYE, minskade kostnader, ett tydligt återhämtat kassaflöde och en rekordhög bruttomarginal.

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Leppänen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release2026-08-14 12:00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release2026-08-14 08:30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release2026-08-14 08:00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet
Analyst Comment2026-08-11 07:02 by
Juha Kinnunen

Optomed Q2'26 förhandskommentar: Vi förväntar oss en återgång till tillväxt och övervakar kassaflödet

Vi estimerar att omsättningen har ökat i takt med att försäljningen av utrustning återhämtat sig från en svag inledning på året.

Optomed
Press release2026-06-23 09:43

Redeye: Optomed: Solid device order

Optomed
Optomed fick en order på 1,8 MEUR för utrustning från USA
Analyst Comment2026-06-22 06:58 by
Atte Riikola

Optomed fick en order på 1,8 MEUR för utrustning från USA

Ordern överstiger hela årets intäkter från utrustning och stärker kassan.

Optomed
Regulatory press release2026-06-18 16:30

Inside Information: Optomed receives a large order in the US

Optomed
Press release2026-05-11 15:16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed